Editor's Choice

Debate recap: Bird Flu Research

Two pathologists dissect a swan in the Danish Food Research Center in Aarhus, Jutland, February 16, 2006. Europe began locking up its one-billion-strong chicken flock on Wednesday after the deadly bird flu virus was found in two more countries on the continent, dealing another blow to battered poultry producers. Germany and Austria are the latest EU countries to report the discovery of dead swans infected with the H5N1 strain of avian influenza, which has spread from Asia to Africa, killed 91 people and led to the destruction of millions of birds. NORWAY OUT DENMARK OUT SWEDEN OUT NO THIRD PARTY SALES REUTERS/Henning Bagger/Scanpix

Dangerous information on a deadly virus

A call to censor scientific research on the deadly bird flu virus has global health officials debating whether such studies are worth the risk. Read our recap of a Harvard School of Public Health discussion on this subject, presented in collaboration with Reuters.  Learn More 

FDA probes candy-like tobacco products

Related Topics

WASHINGTON | Wed Feb 3, 2010 2:11pm EST

WASHINGTON (Reuters) - U.S. health officials are seeking more information about the possible attraction and addiction of flavored, dissolvable tobacco products that regulators worry look too much like candy and can entice children.

The products, made by Reynolds American Inc's R.J. Reynolds Tobacco Co and by Star Scientific Inc, contain powdered "smokeless" tobacco and are brightly colored, with flavors such as coffee and mint.

Companies have argued that the products, which include dissolvable tablets, are aimed at adults who must deal with a growing number of smoking bans in public places as well as those looking to stop smoking.

But the U.S. Food and Drug Administration, in letters to Reynolds and Star Scientific released late Tuesday, said it was concerned that the products could draw in children and teenagers. Use of the products could lead to nicotine addiction and could even cause health problems from the ingestion of too much nicotine, the FDA said.

While laws vary among the U.S. states, most limit tobacco purchase to those 18 and older.

FDA is "concerned that children and adolescents may find dissolvable tobacco products particularly appealing, given the brightly colored packaging, candy-like appearance and easily concealable size of many of these products," Lawrence Deyton, head of the FDA's Center for Tobacco Products, wrote February 1.

The letters come as the FDA prepares to hold its first public meeting on tobacco issues later this year. Agency officials have quickly moved to flex their new oversight of tobacco products after a new law granted them the power last year.

Any move by the FDA to further regulate or even remove dissolvable tobacco products from the U.S. market would be a huge blow to Star Scientific. The one-time cigarette manufacturer has shifted its focus to making products it says expose consumers to lower levels of toxins.

Sara Troy Machir, a spokeswoman for Star Scientific, said the company was not surprised by the letter and would cooperate fully.

"We're happy to share information with them," Machir said, adding that Star's smokeless products -- Ariva and Stonewall -- have been on the market for 10 years.

Representatives for R.J. Reynolds did not immediately respond to requests for comment.

R.J. Reynolds markets three types of similar products under its Camel brand that deliver dissolvable nicotine in tablet, mouth strip and small matchstick-like forms.

The two companies have been embroiled in a patent dispute over some of the technology behind the dissolvable products.

While FDA in its letters to the two companies acknowledged the products are marketed to adults, it nonetheless asked both manufacturers for extensive information on research and marketing practices for the products.

Star Scientific and Reynolds have two months to respond.

The FDA posted the letters on its website here

(Reporting by Susan Heavey, editing by Gerald E. McCormick)

Related Quotes and News

Company
Price
Related News
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.